The Bronchodilator Effect of Salbutamol Administered by IPPB to Patients with Asthma

Spitzer, Simon; Goldschmidt, Z.; Dubrawsky, C.

doi:10.1378/chest.62.3.273

Cited by 8 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…within 20 sec of in halation of a single 250 pg dose from the pressurised aerosol. This rapid effect con trasts with that of salbutamol which has been reported [38] to require 30 min for de velopment of its maximum bronchodilator effect.…”

Section: Rimiterol: a New /^-Selective Agentmentioning

confidence: 56%

A Brief Review of Sympathomimetic Bronchodilators and a Description of a New Selective Agent, Rimiterol Hydrobromide

Muittari¹

1978

Respiration

View full text Add to dashboard Cite

The development of β₂-specific sympathomimetic bronchodilators (rimiterol, salbutamol, terbutaline) has made the basic treatment of asthmatic patients more safe and effective. Despite that, the asthmatics should be under careful control and all patients should be taught the correct way to use their bronchodilator aerosols. If a sympathomimetic drug has lost its effectiveness, the patient should be able to have easy contact to the treating physician or outpatient department.

show abstract

Section: Rimiterol: a New /^-Selective Agentmentioning

confidence: 56%

A Brief Review of Sympathomimetic Bronchodilators and a Description of a New Selective Agent, Rimiterol Hydrobromide

Muittari¹

1978

Respiration

View full text Add to dashboard Cite

show abstract

“…Previous studies of the bronchodilator effect of salbutamol administered by IPPB have: (1) examined doses of salbutamol greater than 5 mg (Choo-Kang et al, 1970); (2) compared IPPB salbutamol (10 mg) and 200 ,ug salbutamol by metered dose inhaler (Choo-Kang and Grant, 1975); and (3) used different groups of patients to compare 5 mg and 2 5 mg of salbutamol by IPPB (Spitzer et al, 1972).…”

Section: Discussionmentioning

confidence: 99%

Aerosol salbutamol administration by IPPB: lowest effective dose.

Ruffin¹,

Obminski²,

Newhouse³

1978

Thorax

View full text Add to dashboard Cite

Ruffin, R E, Obminski, G, and Newhouse, M T (1978). Thorax, 33,[689][690][691][692][693]. Aerosol salbutamol administration by IPPB: lowest effective dose. This study was conducted to determine whether small doses of salbutamol solution, aerosolised and delivered by intermittent positive-pressure breathing (IPPB), would be as effective as the 5 to 10 mg dose usually recommended for inhalational use. In nine asthmatic subjects we found that there was no significant difference between the peak bronchodilator effect of 1-0, 2 5, and 5 0 mg of salbutamol solution as assessed by FEV, (p> O-05). The 5 mg dose of salbutamol solution caused a significantly longer duration of effect than the 10 mg and smaller doses of salbutamol, but it also caused four of the nine subjects to complain of unwanted effects. In addition, a radiotracer technique in four normal subjects showed that an inverse relationship exists between the amount of aerosol deposited in the lungs and the tidal volume of IPPB. The maximum dose deposited in the lungs was about 10% of that initially present in the nebuliser.Intermittent positive-pressure breathing (IPPB) is a mode of administering aerosolised drugs to asthmatic patients (Petty, 1974 Eight subjects were regularly using inhaled salbutamol and beclomethasone diproprionate aerosols; two of them were also taking regular oral theophylline. Each subject was familiar with the use of the IPPB apparatus (Bird Mark 10 respirator). All study days were started after a 15-minute rest period, at the same time of day for each subject. When possible studies were conducted on consecutive days, provided that the baseline FEV1 was within -+15% of the first day's value. No subject received inhaled bronchodilator for eight hours before each study day, the two taking oral theophylline omitted this drug for 689 on 8 May 2018 by guest. Protected by copyright.

show abstract

Chronic obstructive airway diseases. Current concepts in diagnosis and comprehensive care

Hodgkin¹

1975

JAMA: The Journal of the American Medical Association

View full text Add to dashboard Cite

Physicians and paramedical personnel often find the early diagnosis and differentiation of obstructive airway diseases to be a challenging problem. The history and physical examination are often not enough to allow the physician to detect either the presence of, or determine the type of, disease present. Patterns of pulmonary function abnormality to determine the presence of obstructive or restrictive defects are discussed. Guidelines useful in the differentiation of obstructive airway diseases are presented. Once a patient with COAD is assessed, the physician needs to outline a therapeutic program after establishing goals with the patient. These goals include (1) improved ability for the patient to achieve relief from symptoms and (2) improved capacity to carry out the activities of daily living. The therapeutic modalities available for the comprehensive care of patients with COAD are discussed. These include general factors such as patient and family education, avoidance of smoking and other inhaled irritants, avoidance of infection, a minimum stress environment, high fluid intake, and proper nutrition. The appropriate use of the medications most commonly employed in the teatment of these patients, eg, bronchodilators, expectorants, antimicrobials, corticosteroids, cromolyn, digitalis, and diuretics, are individually discussed. The use of such respiratory therapy techniques as aerosol therapy, intermittent positive pressure breathing, and oxygen therapy are considered. Application of the specialty of rehabilitation medicine to patients with obstructive airway disease is described. This includes physical therapy with breathing retraining, clapping and postural drainage, and exercise reconditioning, occupational therapy with attention to energy conservation in activities of daily living, psychological considerations, and vocational rehabilitation. Definite benefits that can be demonstrated if the physician employs this type of systematic respiratory care program include a decrease in the frequency and duration of hospital admissions, socioeconomic gains from reduced hospitalizations, a reduction in anxiety, depression and somatic concern, the return of patients to positions of employment and the establishment of a better quality of life. Persistence in making sure the patient continues in a systematic program, including both pharmacological and nonpharmacological modalities, may be the means of assuring maintenance or even improvement in his health. The day-to-day treatment for the majority of patients should remain in the hands of the primary physician. However, community resources must be established to allow the primary physician to provide these patients with adequate comprehensive respiratory care. Development of three levels of care (the primary physician, community respiratory rehabilitation units, and the regional respiratory center) should make superior respiratory care available to every patient with obstructive airway disease.

show abstract

The Bronchodilator Effect of Salbutamol Administered by IPPB to Patients with Asthma

Cited by 8 publications

References 5 publications

A Brief Review of Sympathomimetic Bronchodilators and a Description of a New Selective Agent, Rimiterol Hydrobromide

A Brief Review of Sympathomimetic Bronchodilators and a Description of a New Selective Agent, Rimiterol Hydrobromide

Aerosol salbutamol administration by IPPB: lowest effective dose.

Chronic obstructive airway diseases. Current concepts in diagnosis and comprehensive care

Contact Info

Product

Resources

About